Filgotinib临床药理学综述
Filgotinib是一种口服优先JAK1抑制剂,经羧酸酯酶2代谢为活性代谢物GS-829845。本文综述其药代动力学特征、药物相互作用及特殊人群影响,显示年龄、性别、轻中度肝肾功能损伤影响极小,药物相互作用风险低,无需常规剂量调整。
要点
- 活性代谢物GS-829845的JAK1选择性与母药相似但活性低10倍,系统暴露高约16-20倍。
- 年龄、性别、种族、轻度肾损伤及轻中度肝损伤对药代动力学无或极小影响。
- 与P-gp抑制剂或诱导剂合用无需调整剂量,药物相互作用风险低。
核心结论
- Filgotinib及其活性代谢物的药代动力学特征支持其作为口服JAK1抑制剂用于类风湿关节炎和溃疡性结肠炎治疗。
研究设计与样本
- 本文为临床药理学综述,系统总结Filgotinib的药代动力学、药物相互作用及特殊人群影响。
主要发现
- Filgotinib口服吸收迅速且广泛,经羧酸酯酶2代谢为活性代谢物GS-829845,后者活性降低10倍但系统暴露增加约16-20倍。
- 母药和代谢物与人血浆蛋白结合率均低(<60%),50-200 mg每日一次剂量范围内系统暴露呈剂量比例增加。
- 食物不影响Filgotinib药代动力学,母药和代谢物终末消除半衰期分别为4.9-10.7 h和19.6-27.3 h。
- Filgotinib主要以代谢物形式经尿液排泄(>80%),母药和代谢物均不影响校正QT间期。
关键数值与推荐
- 年龄、性别、种族、轻度肾损伤及轻中度肝损伤对Filgotinib及其代谢物药代动力学无或极小影响。
- 与P-gp抑制剂和诱导剂合用不影响Filgotinib药代动力学至需调整剂量的程度。
临床怎么用
- Filgotinib在轻中度肝肾功能损伤患者及不同年龄、性别、种族人群中无需调整剂量。
- 与常见抗炎药物合用无需担心临床显著药物相互作用,与P-gp抑制剂或诱导剂合用亦无需调整剂量。
局限性
- 原文未报告重度肾损伤或重度肝损伤对药代动力学的影响。
- 原文未报告儿童人群的药代动力学数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Filgotinib (GS-6034, formerly GLPG0634; Jyseleca®) is an oral, preferential Janus kinase (JAK)-1 inhibitor. Preferential inhibition of JAK1 modulates a subset of proinflammatory cytokines within the JAK-signal transducer and activator of transcription pathway, which differ from those inhibited by JAK2 or JAK3. Filgotinib is absorbed extensively and rapidly after oral dosing and is metabolized by carboxylesterase isoform 2 to form its primary active metabolite, GS-829845. The primary metabolite has a similar JAK1 selectivity profile but reduced activity (by 10-fold) and increased systemic exposure (approximately 16- to 20-fold) compared with the parent compound. Both the parent and the metabolite demonstrate low binding to plasma proteins in humans (< 60%). Systemic exposures of filgotinib and its primary metabolite increase dose proportionally over a 50- to 200-mg once-daily dose range. Food does not affect the pharmacokinetics of filgotinib. Consistent with their terminal elimination half-lives (4.9-10.7 h for filgotinib and 19.6-27.3 h for the primary metabolite), steady state in plasma is reached by day 2 for filgotinib and day 4 for its metabolite. Filgotinib is mainly eliminated in the urine as the metabolite (> 80%). Intrinsic factors such as age, sex, race, mild renal impairment, and mild-to-moderate hepatic impairment have either no or minimal impact on the pharmacokinetics of filgotinib and its primary metabolite. Filgotinib has a low drug-drug interaction potential, without clinically significant interactions with commonly coadministered medications in patients with inflammatory diseases. Both filgotinib and its primary metabolite are substrates of P-glycoprotein (P-gp); however, coadministration with P-gp inhibitors and inducers does not affect filgotinib pharmacokinetics sufficiently to warrant dose adjustment. Neither filgotinib nor its primary metabolite affect the corrected QT interval (calculated using Fridericia's correction formula). Filgotinib is approved for the treatment of rheumatoid arthritis and ulcerative colitis in Europe, the UK, and Japan.
引用
- Namour F, Anderson K, Nelson C, et al. Filgotinib: A Clinical Pharmacology Review. Clin Pharmacokinet. 2022. PMID: 35637376. doi:10.1007/s40262-022-01129-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。